human cells for preclinical testing and scalable EV production

human telomerized cells
as advanced in vitro models

Highly differentiated human cells are becoming increasingly important as reliable in vitro test systems in biomedicine, toxicology, and biotechnology. While primary human cells retain characteristics of their in vivo counterparts, their application is often limited by a finite lifespan. These limitations reduce the reproducibility and standardization of many in vitro assays.

To address this, Evercyte has developed a broad portfolio of telomerized human cell lines. By introducing the catalytic subunit of human telomerase (hTERT) into primary cells, we generate cell lines that maintain a stable phenotype and functional integrity while being capable of continuous expansion. Each line undergoes thorough characterization to ensure its relevance and suitability for a wide range of applications.

These telomerized cells serve as valuable tools for the development of standardized in vitro assays and integration into more complex systems such as organ-on-a-chip platforms. Our HUVEC/TERT2 and LF/TERT309 cells have been incorporated into commercially available microfluidic kits to model angiogenesis and microvascular network formation. Our RPTEC/TERT1 cells were embedded within an extracellular matrix to create 3D human renal proximal tubules in vitro and were recently featured in a Nikon application note showcasing their use in a Nortis Inc. MPS for high-resolution imaging of primary cilia in a 3D proximal tubule model.

With their extended lifespan and physiological relevance, Evercyte’s telomerized cells bridge the gap between primary cells and traditional immortalized models, allowing researchers to create more reproducible and human-relevant in vitro systems.

human telomerized cells
as innovative EV cell factories

Evercyte’s telomerized mesenchymal stromal cells (MSC/TERT) offer a powerful and reliable platform for the production of extracellular vesicles (EVs) for research and therapeutic applications. While MSCs are widely recognized for their regenerative properties, it is now well established that much of their therapeutic potential is mediated through their secreted EVs.

Unlike primary MSCs, which are limited by donor variability, finite lifespan, and inconsistent yields, Evercyte’s telomerized MSCs overcome these challenges by enabling continuous expansion without loss of phenotype, characteristics or function. This ensures a stable source of EVs with consistent quality, critical for scalable and standardized production for biomedical applications.

To support a wide range of applications, Evercyte has developed telomerized MSCs derived from various tissue sources, including adipose tissue, bone marrow, Wharton’s jelly, different regions of the placenta (amnion and chorionic plate), and endometrium. Each which may influence the composition, functionality, and therapeutic potential of the EVs produced. This diversity enables researchers to select the most appropriate cell line for their specific needs, offering unique advantages for specific therapeutic or research applications.

Evercyte’s telomerized MSC cell lines combine the regenerative and immunomodulatory potential of primary MSCs with the practical advantages of a continuously growing system, making them ideal cell factories for EV-based therapeutics.